Pfizer swings to a profit, but misses Street expectations

NEW YORK (AP) — Pfizer swing to a small profit in the fourth-quarter as rising medicine sales helped offset big increases in spending on research and production, but it still missed Wall Street expectations.

The New York drugmaker, the first company to get U.S. emergency use authorization for a COVID-19 vaccine, reported fourth-quarter net income of $594 million, or 10 cents per share. A year earlier, Pfizer posted a loss of $337 million, or 6 cents per share, mainly due to a big writedown on the value of eczema drug Eucrisa.

Excluding one-time items, adjusted earnings came to 42 cents per share, or 4 cents shy of Wall Street projections, according to a survey by Zacks Investment Research.

The maker of the world’s top-selling vaccine, Prevnar 13 for preventing pneumonia and related bacterial diseases, reported revenue of $11.68 billion, up 12% from 2019’s fourth quarter. That beat Wall Street forecasts for $11.01 billion.

Pfizer said it expects full-year earnings in the range of $3.10 to $3.20 per share, with revenue in the range of $59.4 billion to $61.4 billion.

Shares are essentially flat before the opening bell.

_____

Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PFE at https://www.zacks.com/ap/PFE

Copyright © 2021 . All rights reserved. This website is not intended for users located within the European Economic Area.

Comments

Sign up for breaking news alerts